Insider Selling: DexCom, Inc. (NASDAQ:DXCM) EVP Sells 500 Shares of Stock

DexCom, Inc. (NASDAQ:DXCM - Get Free Report) EVP Michael Jon Brown sold 500 shares of DexCom stock in a transaction on Monday, June 16th. The shares were sold at an average price of $82.80, for a total value of $41,400.00. Following the transaction, the executive vice president now directly owns 95,102 shares of the company's stock, valued at approximately $7,874,445.60. The trade was a 0.52% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Michael Jon Brown also recently made the following trade(s):

• On Friday, May 23rd, Michael Jon Brown sold 10,000 shares of DexCom stock. The stock was sold at an average price of $84.28, for a total transaction of $842,800.00.

DexCom Trading Down 1.0%

Shares of DexCom stock traded down $0.82 during trading on Wednesday, reaching $81.01. 4,738,215 shares of the company were exchanged, compared to its average volume of 4,345,532. The business has a 50-day moving average price of $79.25 and a 200-day moving average price of $79.38. The firm has a market capitalization of $31.76 billion, a price-to-earnings ratio of 60.46, a P/E/G ratio of 1.77 and a beta of 1.46. The company has a quick ratio of 1.32, a current ratio of 1.50 and a debt-to-equity ratio of 0.55. DexCom, Inc. has a twelve month low of $57.52 and a twelve month high of $117.49.

DexCom (NASDAQ:DXCM - Get Free Report) last announced its quarterly earnings results on Thursday, May 1st. The medical device company reported $0.32 earnings per share for the quarter, missing analysts' consensus estimates of $0.33 by ($0.01). DexCom had a return on equity of 30.05% and a net margin of 12.90%. The firm had revenue of $1.04 billion for the quarter, compared to the consensus estimate of $1.02 billion. During the same period in the prior year, the business earned $0.32 earnings per share. The company's revenue for the quarter was up 12.5% compared to the same quarter last year. Sell-side analysts anticipate that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have commented on the stock. Wall Street Zen upgraded shares of DexCom from a "hold" rating to a "buy" rating in a research report on Friday, June 6th. The Goldman Sachs Group assumed coverage on DexCom in a report on Friday, May 30th. They issued a "buy" rating and a $104.00 target price on the stock. Truist Financial started coverage on DexCom in a research report on Monday. They set a "buy" rating and a $102.00 price target on the stock. Robert W. Baird dropped their price target on DexCom from $115.00 to $105.00 and set an "outperform" rating for the company in a report on Friday, May 2nd. Finally, Canaccord Genuity Group lifted their price objective on DexCom from $103.00 to $106.00 and gave the company a "buy" rating in a research report on Friday, May 2nd. Four equities research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and three have issued a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $98.50.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in DXCM. Forvis Mazars Wealth Advisors LLC lifted its holdings in shares of DexCom by 0.7% during the 4th quarter. Forvis Mazars Wealth Advisors LLC now owns 17,481 shares of the medical device company's stock valued at $1,359,000 after purchasing an additional 118 shares in the last quarter. Horizon Investments LLC raised its holdings in DexCom by 2.2% during the 1st quarter. Horizon Investments LLC now owns 5,608 shares of the medical device company's stock worth $383,000 after buying an additional 123 shares during the period. Principal Securities Inc. raised its holdings in DexCom by 3.4% during the 4th quarter. Principal Securities Inc. now owns 4,069 shares of the medical device company's stock worth $316,000 after buying an additional 135 shares during the period. Larson Financial Group LLC lifted its stake in DexCom by 40.5% in the fourth quarter. Larson Financial Group LLC now owns 475 shares of the medical device company's stock valued at $37,000 after buying an additional 137 shares in the last quarter. Finally, Nia Impact Advisors LLC boosted its holdings in shares of DexCom by 1.4% in the fourth quarter. Nia Impact Advisors LLC now owns 9,850 shares of the medical device company's stock valued at $766,000 after buying an additional 140 shares during the period. 97.75% of the stock is currently owned by institutional investors.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.